0
Abstract: Poster Presentations |

IMPROVED SURVIVAL IN A SUBSET OF HISPANIC PATIENTS FROM STRIDE-3 WITH PULMONARY ARTERIAL HYPERTENSION TREATED WITH SITAXSENTAN FREE TO VIEW

Tomas Pulido, MD*; Ivonne Roquet, MD; Efrén Santos, MD; Tania Rueda, MD; Gabriel Pérez, MD; Rocio Gutiérrez, RN; Ma. Teresa Miranda, RN; Hector Peña, MD; Julio Sandoval, MD
Author and Funding Information

Instituto Nacional de Cardiologia, Ignacio Chávez, Mexico City, Mexico


Chest


Chest. 2008;134(4_MeetingAbstracts):p161001. doi:10.1378/chest.134.4_MeetingAbstracts.p161001
Text Size: A A A
Published online

Abstract

PURPOSE: Pulmonary arterial hypertension (PAH) is a progressive disease with a median survival of 2.8 years from diagnosis. Recently, the development of target-specific drugs including endothelin receptor antagonists, have improved time to clinical worsening and survival in patients with PAH. Sitaxsentan is a highly-selective endothelin-A receptor antagonist with proven efficacy in exercise capacity and quality of life in patients with PAH; however, limited data are available on the long-term survival of patients with PAH treated with this drug. Within our center in Mexico City, we sought to evaluate the effects on survival of long-term treatment with sitaxsentan, in a subset of patients from the STRIDE-3 trial.

METHODS: STRIDE-3, is an ongoing, open-label trial evaluating the long-term safety of sitaxsentan 100mg qd in PAH. Survival was assessed in patients treated with sitaxsentan for up to 4 years and rates compared with predicted survival according to the NIH equation at 1, 2 and 3 years.

RESULTS: Thirtysix patients with PAH from our department, who were included in STRIDE-3, were analysed. Of these, 33 were diagnosed with idiopathic PAH and 3 with PAH associated with connective tissue disease (mPAP 66±22mmHg, RAP 9.7±6mmHg, CI 2.6±0.9L/min/m2). All 36 patients (30 females, age range 30±11years) were treated with sitaxsentan 100mg qd long-term plus conventional therapy (mean time 148±54weeks; range 26−220weeks). At baseline, patients were in WHO functional class II, n=31; or III, n=5, and 6 minute walk distance was 320±98m. After treatment with sitaxsentan, cumulative survival in patients was 96%, 79% and 75% at 1, 2 and 3 years, respectively, versus predicted survival of 71%, 60% and 50%, based on the NIH equation (p<0.05). Four patients withdrew voluntarily from the study (withdrawal was not drug related). Five patients required combination therapy (sildenafil) because of clinical deterioration and 18 patients remain on sitaxsentan monotherapy at 3 years.

CONCLUSION: Sitaxsentan improves long-term survival in patients with PAH in WHO functional class II and III.

CLINICAL IMPLICATIONS: Sitaxsentan monotherapy is another option for target-specific treatment of pulmonary arterial hypertension.

DISCLOSURE: Tomas Pulido, Grant monies (from industry related sources) The author has been a principal investigator for some of the STRIDE studies and his institution has received research grants from Encysive.; No Product/Research Disclosure Information

Wednesday, October 29, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543